Corvus Pharmaceuticals, Inc. (CRVS)
$14.16-$0.56 (-3.80%) Today
Peter A. Thompson - DirectorCorvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 21,700 | $250K |
| Grant or award | 5 | 75,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
16 Form 4 filings on record, the earliest from Dec 23, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David Scott Moore | Open-market purchase | Common Stock | 21,700 | $11.53 | $250K | |
| David Scott Moore | Grant or award | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Ian T. Clark | Grant or award | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Linda Grais | Grant or award | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson | Grant or award | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Den Broek Richard van | Grant or award | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Richard A. Md Miller - Officer | Open-market purchase | Common Stock | 5,000 | $12.05 | $60K | |
| Richard A. Md Miller - Officer | Open-market purchase | Common Stock | 1,932 | $12.01 | $23K | |
 Andrew C. Chan | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 30,000 | $15.00 | $450K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $9.70 | $146K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $12.50 | $188K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $3.61 | $54K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $2.00 | $30K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $3.27 | $49K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $2.74 | $41K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $2.60 | $39K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $0.99 | $15K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $2.49 | $37K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $0.97 | $14K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $1.64 | $25K | |
| Peter A. Thompson - Director | Option exercise | Common Stock | 15,000 | $2.12 | $32K | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peter A. Thompson - Director | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| David Scott Moore | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 1,397,684 | $3.50 | $4.89M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 1,176,332 | $4.16 | $4.89M | |
| ORBIMED ADVISORS LLC - Director | Other | Common Warrants (right to buy) | 1,397,684 | $0.00 | - | |
| Peter A. Thompson - Director | Other | Common Stock | 1,397,684 | $3.50 | $4.89M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 1,176,332 | $4.16 | $4.89M | |
| Peter A. Thompson - Director | Other | Common Warrants (right to buy) | 1,397,684 | $0.00 | - | |
| Richard A. Md Miller - Officer | Option exercise | Common Stock | 559,073 | $3.50 | $1.96M | |
| Richard A. Md Miller - Officer | Option exercise | Warrant (Right to Buy) | 559,073 | - | - | |
| Jeffrey Arcara - Officer | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Leiv Lea - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Richard A. Md Miller - Officer | Grant or award | Stock Option (Right to Buy) | 750,000 | $0.00 | - | |
| William Benton Jones - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - |
Corvus Pharmaceuticals, Inc. (CRVS) had 5 insider filings in the last 90 days, with the most recent on 2026-06-15. The full record for CRVS runs to 16 Form 4 filings, the earliest from 2024-12-23. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
1 insider purchase of CRVS was filed in the last 90 days, totaling $250K.
No insider sales of CRVS were filed in the last 90 days. 2 sales are on record for this company.
This page tracks CRVS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CRVS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
